Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| NS Georgia | Pharma | 11.5% | 44th pct | 110 |
| Pulparmi | Pharma | 8.1% | 35th pct | 110 |
| Med Treideri | Pharma | 1.3% | 17th pct | 110 |
| Maksparma | Pharma | — | no FY data | 110 |
| Anshen Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2023 (4 of 5).
| Line item | Med Treideri | Pulparmi | NS Georgia | Maksparma | Anshen Pharma |
|---|---|---|---|---|---|
| Total Current Assets | 1,963 | 329 | 3,051 | — | — |
| Total Non-Current Assets | 46 | 18 | 241 | — | — |
| TOTAL ASSETS | 2,009 | 347 | 3,292 | — | — |
| Total Current Liabilities | 196,299 | 240 | 284 | — | — |
| Total Non-Current Liabilities | -195,035 | 0 | 0 | — | — |
| TOTAL LIABILITIES | 1,264 | 240 | 284 | — | — |
| Total Equity | 745 | 107 | 3,008 | — | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | — | — |
| Total Debt | 274 | 0 | 0 | — | — |
| Cash & Equivalents | 60 | 8 | 426 | — | — |
| Net Debt | 214 | -8 | -426 | — | — |
Not every picked company reports every selected year — FY2024: no filing for Anshen Pharma and Maksparma. Those cells are left blank (no filing), not zero.